The CDC recommends the Pfizer RSV vaccine during pregnancy
An advisory panel of the US Centers for Disease Control and Prevention on Friday recommended the respiratory syncytial virus, or RSV, vaccine during pregnancy, which offers additional protection to newborns against the disease.
The panel voted 11-1 to recommend giving Pfizer's Abrysvo between 32 and 36 weeks of pregnancy.
CDC Director Dr. Mandy Cohen formally endorsed the recommendation.
The Food and Drug Administration approved Abrysvo for use in pregnant women last month, but it also needed approval from the CDC before it could be added to the list of "maternal vaccines" recommended before birth. It also comes after the FDA and the CDC approved nirsivumab, an RSV antibody injection for infants and young children, earlier this summer. Nirsivamab, made by Sanofi and AstraZeneca and sold under the brand name Beyfortus, has been found to prevent "severe RSV disease," the CDC said. It is meant to be given just before or during the RSV season, which runs from October to March.
According to the CDC, RSV is the leading cause of hospitalization for infants. How FDA's Chief Immunization Office Plans for COVID-19 Booster and Flu Vaccine by Fall 2023
In June, the CDC approved both Abrysvo and GSK's Arexvy vaccine to protect against RSV in adults 60 and older. Last month, Arexvy became the first RSV vaccine to receive FDA approval.
According to the CDC, 58,000 to 80,000 children under the age of 5 are treated for RSV each year in the United States, while 60,000 to 160,000 people over the age of 65 are hospitalized for the disease each year.
Healthcare is constantly evolving, especially in the area of vaccines. One of the most important developments in recent years has been the Pfizer RSV (Respiratory Syncita Virus) vaccine during pregnancy offered by the Centers for Disease Control and Prevention (CDC). This decision has important implications for the health of expectant mothers and their newborns. In this article, we will explore why the CDC approves the Pfizer RSV vaccine during pregnancy and how important this recommendation is.
Respiratory syncytial virus, commonly known as RSV, is a highly contagious virus that primarily affects the respiratory tract. It can cause serious respiratory infections, especially in babies and young children. RSV infections often cause flu-like symptoms, but can progress to more severe conditions such as bronchitis and pneumonia in vulnerable populations. Pregnant women and RSV: Pregnant women, young infants, and older adults are among the groups at higher risk for serious RSV infections. During pregnancy, a woman's immune system changes to adapt to the growing fetus, making her more susceptible to certain infections. This vulnerability underscores the need to protect against RSV, especially for expectant mothers.
The CDC's recommendation to give the Pfizer RSV vaccine during pregnancy is based on extensive research and clinical trials. This vaccine was developed to provide passive immunity against RSV to both pregnant women and their newborns.
When pregnant women receive Pfizer's RSV vaccine, their bodies produce antibodies against RSV. These antibodies are then transferred across the placenta to the developing fetus, providing the baby with protection during the first critical months of life when exposed to RSV.
Passive immunity from the mother's vaccinations can help protect the newborn from RSV infections, which can be especially important in infants. Reducing Healthcare Burden: By preventing neonatal RSV infections, the CDC recommendation aims to reduce the burden on healthcare systems, including hospitalizations and medical costs associated with treating severe cases of RSV. Community protection: Widespread vaccination of pregnant women can also promote herd immunity, making it more difficult for RSV to spread in communities. Safety Considerations: The safety of vaccines, especially during pregnancy, is paramount. Extensive clinical trials have shown that the Pfizer RSV vaccine is safe and effective in pregnant women and their babies. It undergoes rigorous testing to ensure that the benefits of vaccination outweigh any potential risks. Conclusion: The CDC's recommendation for use of the Pfizer RSV vaccine during pregnancy is an important step forward in protecting the health of expectant mothers and their newborns. It emphasizes the importance of preventive measures to combat the potentially serious consequences of RSV infections in infants. As health science advances, these recommendations remind us of our ongoing commitment to improving public health and protecting vulnerable populations. Pregnant women should consult with their doctor to discuss the suitability of the vaccine for their individual circumstances and to answer any questions or concerns.
You must be logged in to post a comment.